Celldex Drug Trial Success Overshadowed By Safety Concerns

Economic Times Markets · stocks

Celldex Therapeutics announced its experimental drug barzolvolimab showed significant reduction in disease activity for chronic skin condition patients in late-stage trials. However, shares dropped nearly 15% due to investor focus on two probable anaphylaxis cases. The drug met primary endpoints, with 42.1% to 45.7% of patients showing complete response at 12 weeks. Celldex plans a U.S. regulatory filing in 2027, expecting potential label warnings for hypersensitivity.